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Differential responsiveness of MET 
inhibition in non-small-cell lung 
cancer with altered CBL
Yi-Hung Carol Tan1, Tamara Mirzapoiazova2, Brian M. Won1, Li Zhu3, Minu K. Srivastava3, 
Everett E. Vokes1, Aliya N. Husain4, Surinder K. Batra5,6, Sherven Sharma3 & Ravi Salgia2
Casitas B-lineage lymphoma (CBL) is an E3 ubiquitin ligase and a molecule of adaptor that we have 
shown is important for non-small-cell lung cancer (NSCLC). We investigated if MET is a target of CBL 
and if enhanced in CBL-altered NSCLC. We showed that CBL wildtype cells have lower MET expression 
than CBL mutant cells. Ubiquitination of MET was also decreased in CBL mutant cells compared to 
wildtype cells. Mutant cells were also more sensitive to MET inhibitor SU11274 than wild-type cells. 
sh-RNA-mediated knockdown of CBL enhanced cell motility and colony formation in NSCLC cells, and 
these activities were inhibited by SU11274. Assessment of the phospho-kinome showed decreased 
phosphorylation of pathways involving MET, paxillin, EPHA2, and VEGFR. When CBL was knocked 
down in the mutant cell line H1975 (erlotinib-resistant), it became sensitive to MET inhibition. Our 
findings suggest that CBL status is a potential positive indicator for MET-targeted therapeutics in 
NSCLC.
Lung cancer is the second most common cancer in both men and women, and it has a very poor prognosis1. 
Non-small-cell lung cancer (NSCLC), a type of lung cancer, accounts for 80% of all lung cancers, and it has a 
5-year survival rate of approximately 15%2. Despite recent developments in targeted therapeutic approaches and 
immune-therapies, the overall morbidity and mortality of NSCLC have not changed substantially over the past 25 
years. Therefore, there is an urgent need to identify and develop novel targeted therapies.
Receptor tyrosine kinases (RTKs) are involved in cell cycle, proliferation, and differentiation in cancer3, 4. 
Multiple studies have shown that RTKs are overexpressed as oncogenes in various cancers including lung cancer5, 6. 
Therefore, targeting RTKs is a new strategy for inhibiting tumor growth7. Many studies have indicated that CBL 
(Casitas B-lineage lymphoma) plays an important role in down-regulating RTKs based on its E3 ubiquitin ligase 
activity8, 9. The CBL protein family belongs to a class of E3 ubiquitin ligases10. The CBL protein associates with 
the endocytosis mechanism, and plays a crucial role in terminating RTK signaling10. The tyrosine kinase binding 
(TKB) and RING finger domains of CBL are the crucial domains for regulating RTK signaling, particularly EGFR 
and MET regulation7.
Mutations in CBL were first reported in human acute myeloid leukemia (AML), and over the past several 
years, CBL mutations have been identified in other types of leukemia11, 12. Our previous studies were the first 
to report CBL mutations in solid tumors, such as lung cancer13. Eight novel somatic mutations were found in 
Caucasian, Taiwanese, and African American patients with NSCLC. Moreover, loss of heterozygosity (LOH) was 
detected in 22% of NSCLC cases, and none of these patients’ samples had any mutations in their remaining copy 
of CBL13. Of the eight novel CBL mutations, three displayed relevant E3 ubiquitin activity; S80N/H94Y, Q249E, 
and W802*. Ectopic expression of these mutations in NSCLC cell lines enhanced cell proliferation and motility13. 
In contrast, ectopic expression of wild-type (WT) CBL inhibited NSCLC cell proliferation in vitro and tumor 
formation in vivo14. Interestingly, our previous research showed EGFR expression was similar in CBL WT and 
CBL mutant (Mt) cells.
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MET has been identified as an important target in various human cancers, especially in lung cancer. MET sig-
naling plays a critical role in tumor cell survival, proliferation, and migration. MET is mutated (juxtamembrane 
domain) and amplified in 4% and 5%, of lung cancer cases, respectively15, 16. In addition, more than 50% of lung 
cancer patients have MET overexpression15, 16. NSCLC patients with MET mutations and amplifications, as well 
as MET overexpression, displayed stronger responses to MET inhibitors17–19.
To understand whether the different CBL Mts affect the E3 ubiquitin ligase activity, EGFR was investigated as 
a model target for CBL E3 ubiquitin function in our previous experiment13. The results showed that all of the CBL 
Mts had similar ubiquitination of the activated EGFR to the CBL WT protein. The ubiquitination of MET, how-
ever, was decreased in A549 cells that transiently expressed CBL Mts relative to CBL WT cells. The preliminary 
results demonstrated that the substrate of CBL E3 ubiquitin activity was MET but not EGFR. Hence, in the cur-
rent study, we sought to not only determine if MET is a target for CBL-mediated degradation and ubiquitination 
in NSCLC, and also whether it could serve as a novel therapeutic target in lung cancer.
Results
MET expression is increased in CBL mutants and shRNA knockdown cells. To investigate whether 
CBL mutations we identified previously affect the protein expression regulation of both EGFR and MET in 
NSCLC, we first used anti-CBL shRNA to silence CBL in A549 cells that had very low CBL endogenous protein 
expression. We then overexpressed CBL WT and CBL Mts S80N/H94Y, Q249E, V391I, and W802* to make 
stable clones. Sh-RNA knockdown CBL (sh-CBL) in H358 cells that had high CBL expression was also used. 
MET expression was decreased in A549 CBL WT cells and increased in most of A549 CBL Mts and H358 sh-CBL 
knockdown cells by immunoblotting (Fig. 1). A549 CBL Mt-S80N/H94Y and Q249E showed significantly 
increasing MET expression and A549 CBL Mt- V391I and W802* showed only slightly higher MET expres-
sion compared to A549 CBL WT (Fig. 1). However, EGFR protein expression did not show differences in A549 
isogenic CBL WT or Mt cells13 or in H358 shRNA knockdown cells (Fig. 1A and B).
E3 ubiquitin ligase function of CBL mutations and knockdown is decreased in degrading 
MET. We previously showed that EGFR protein expression had no difference while CBL mutations occurred13. 
To investigate whether CBL mutations affect the E3 ubiquitin activity, immunoprecipitation followed by immu-
noblotting showed that ubiquitin decreased in A549 CBL Mt and H358 sh-CBL cells compared with A549 CBL 
WT and H358 sh-control cells (Fig. 1C and D). MET protein expression showed higher expression in A549 CBL 
Mt and H358 sh-CBL cells compared to A549 CBL WT and H358 sh-control cells.
CBL mutations and knockdown cells increase the sensitivity of SU11274 treatment in cell sur-
vival and migration. Since CBL Mt and knockdown cells have higher MET protein expression than CBL 
WT cells, we hypothesized that CBL Mt and knockdown cells would be more sensitive to MET inhibitory treat-
ment. To investigate whether overexpression of MET enhanced the sensitivity of drug treatment, cell viability was 
assayed. Results for cell survival of SU11274 treatment in empty vector (EV) control and CBL Mt cells; S80N/
H94Y, Q249E, V391I, and W802*, which have low CBL/high MET expression were 39.8%, 39.9%, 21.1%, 19.3%, 
and 23.9%, respectively. CBL WT cells showed a 66.7% of survival rate after SU11274 treatment (Fig. 2).
In addition, we performed a cell migration (wound healing) assay in H358 sh-CBL isogenic cells. The results 
showed that the wound gap in H358 sh-CBL cells was smaller than the gap in sh-control cells. When treated with 
MET inhibitor SU11274, sh-CBL cells showed a larger wound gap than the sh-control cells. Thus, H358 sh-CBL 
cells, which had higher expression of MET compared with sh-control cells, had higher migration ability than 
the control cells but migration ability decreased after SU11274 treatment (Fig. 3). In summary, cell survival and 
migration assays both showed that CBL Mts and knockdown cells increased the sensitivity of MET inhibitor 
SU11274.
CBL knockdown cells enhance colony formation and are more sensitive to MET inhibitor 
SU11274. In our previous studies, H358 sh-CBL cells had increased cell proliferation compared with 
sh-control cells13. In addition, CBL WT cells had decreased cell and tumor growth13, 14. To evaluate CBL Mt/
knockdown effects in culture, a soft agar colony formation assay was performed by first using H358 sh-CBL cells. 
The results showed H358 sh-CBL cells had more colony formations and the colony size was larger than sh-control 
cells (Fig. 4).
H226 sh-CBL cells treated with SU11724 showed a larger number of colonies inhibition than sh-control cells 
(Fig. 4D).
CBL mutations affect multi phospho-RTKs on the phospho-kinome. We determined the 
phospho-kinome activity of CBL Mts S80N/H94Y, Q249E, and W802* after SU11274 treatment. The analysis 
showed the receptor tyrosine kinase activity of most peptides was down regulation, and a total of 32 peptides 
from 28 genes were significantly modulated (p < 0.05) (Fig. 5A). Three tyrosine kinase phosphorylation sites 
were significantly detected down regulated in S80N/H94Y, Q249E, and W802* CBL mutants (p < 0.05): CD79A 
molecule, immunoglobulin-associated alpha also known as B-cell antigen receptor complex-associated pro-
tein alpha chain and MB-1 membrane glycoprotein (CD79A) (Tyr86/92); paxillin (PAXI) (Tyr118); and FES 
proto-oncogene (FES) (Tyr713). The W802* CBL mutation showed the most dramatic tyrosine kinase phospho-
rylation inhibition. In addition, VEGFR3, also known as fms-related tyrosine kinase 4 (FLT4) (Tyr1063/1068), 
and phospholipase C gamma 1 (PLCG1) (Tyr783) were the only two sites found to be significantly upregulated 
(p < 0.05) (Fig. 5A). The protein expression was selectively validated by immunoblotting. p-CD79A, p-PECAM, 
p-EPHA2, and p-p85 PI3K were all found significantly different than CBL WT in all three mutants (Fig. 5B).
To understand the network of affected peptides, a signaling transduction network with the 32 down-regulated 
peptides was predicted and created by IPA (Fig. 5C). The analysis revealed that PTEN signaling was the top 
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canonical pathway (p < 0.001) involved in MET inhibition in CBL Mt cells. In addition, carbohydrate metabo-
lism, cellular function/maintenance, and cell-to-cell signaling/interaction were the networks which had the most 
affected peptides involved. Moreover, the genes of the most affected peptides are involved in cell cycle, cell death, 
and cell survival related to cancer and respiratory disease (Table 1).
EGFR mutant/MET wild-type cells with CBL knockdown enhance the sensitivity of inhibition by 
MET inhibitor SU11274. Using the University of Chicago Thoracic Oncology Research Program (TORP) 
database, we found patients with CBL alterations also had other driver gene alterations. Table 2 lists MET, EGFR, 
or KRAS alterations of each patient who had a CBL alteration and the treatment outcome. Most patients with CBL 
alterations had EGFR mutations but not MET mutations. Also, most patients with CBL alterations and EGFR 
mutations had a poor response to the treatment. Hence, to investigate the finding of clinical results and whether 
CBL could be a positive indicator for MET-targeted therapeutics in lung cancer, we used the EGFR L858R/T790M 
mutation cell line H1975. H1975 cells have WT MET. H1975 sh-CBL cells remained resistant to the EGFR inhib-
itor, erlotinib (Fig. 6). However, H1975 sh-CBL cells became sensitive to SU11274, a MET inhibitor, compared to 
sh-control and parental H1975 cells (Fig. 6).
Figure 1. Ubiquitination and expression analysis of various CBL mutants. (A) A549 shRNA knockdown 
CBL cells were transiently transfected with various CBL mutants (SH: S80N/H94Y, Q: Q249E, V: V391I, W*: 
W802*) and wild-type (WT). MET protein showed low expression in CBL WT and high expression in CBL 
Mts isogenic cells. Protein expression was quantified and indicated with the fold change numbers shown below 
each immunoblot in comparison with loading control β-actin. (B) MET and EGFR expression of H358 sh-
control and sh-CBL. MET showed higher expression in sh-CBL than sh-control cells. EGFR had no difference 
in sh-control and sh-CBL. (C) A549 cells transiently transfected with empty vector (EV) or CBL WT and 
Mts (SH: S80N/H94Y, Q: Q249E, V: V391I, W*: W802*). Whole cell lysates were IP with anti-MET antibody 
and IB with anti-Ub antibody. IB with anti-HA antibody for transfection efficiency and β-actin for loading 
control of the IP. The results showed the ubiquitination of MET were decreased in A549 cells that transiently 
expressed CBL mutants relative to CBL WT cells. (D) H358 sh-Control and sh-CBL cell lysates were IP with 
anti-MET antibody and IB with anti-Ub antibody β-actin for loading control of the IP. The results showed 
the ubiquitination of MET were decreased in sh-CBL cells relative to sh-control cells. Each protein lysates of 
separated blot of were collected in the same time period for and the lysates were loaded in one gel per antibody 
staining.
www.nature.com/scientificreports/
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CBL knockdown cells increase tumor metastasis and inhibit tumor growth of MET inhibitor 
PHA665752 treatment in vivo. We investigated whether CBL knockdown affects tumor growth in vivo 
using A549 sh-CBL and H358 sh-CBL cells in mouse xenograft studies. Both A549 sh-CBL and H358 sh-CBL 
Figure 2. Cell survival of CBL Mts after treatment with MET inhibitors. A549 CBL isogenic cells with empty 
vector (EV) or CBL wild-type (WT) and mutations (SH: S80N/H94Y, Q: Q249E, V: V391I, W*: W802*). MET 
inhibitor SU11274 was treated 1 μM for 48 hr. CBL Mts showed more sensitivity to SU11274 treatment than 
CBL WT.
Figure 3. Cell migration of sh-CBL cells treated with MET inhibitor SU11274. Wound healing assay was 
performed in H358 sh-control and sh-CBL cells. The results showed sh-CBL cells had higher migration ability 
than sh-Control cells. After treated with MET inhibitor SU11274, sh-CBL cells had more sensitive migration 
inhibition by SU11274 than sh-control cells.
www.nature.com/scientificreports/
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animals showed less tumor growth than the sh-control animals (Fig. 7A–C). However, haematoxylin and eosin 
(H & E) stain of lung sections showed both A549 sh-CBL and H358 sh-CBL animals had more tumor colonies in 
the lung than sh-control groups (Fig. 7D and E).
To investigate whether CBL can be a positive indicator for MET-targeted therapeutics in lung cancer, H358 
sh-control/sh-CBL xenografts were treated with MET inhibitor PHA665752. The results showed that the lungs 
of animals in the H358 sh-CBL group had more tumor inhibition than the lungs of animals in the sh-control 
group. Furthermore, no tumor metastasis in the lung was found in animals in the sh-CBL group with PHA665752 
treatment (Fig. 8).
The role CBL plays in lung cancer tumorigenesis remains unclear. From the year of 2012 to 2016, 189 NSCLC 
patients were enrolled in next generation sequencing platforms (FoundationONE, Foundation Medicine, 
Cambridge, MA) at The University of Chicago Medicine lung cancer program. We have found that 5.3% (10/189) 
of patients have CBL alterations (Table 2), which is very similar to our previous finding13. In FoundationONE’s 
report, given the mutation rates in CBL as well as alterations in RTKs such as EGFR, MET, or KRAS, it is likely 
that their combined effect could alter the patient treatment outcome and also be synergistic in promoting tumor-
igenesis. In addition, the report from the University of Chicago’s TORP database showed patients who had CBL 
and EGFR alterations had a poor outcome in response to EGFR treatment. This study was performed to show an 
alternative therapeutic strategy in lung cancer.
In the current study, immunoblotting and PamGene platforms were utilized to investigate the effective tar-
get genes of representative CBL Mts, S80N/H94Y double mutation, Q249E, V391I, and W802* in lung cancer. 
Relative to CBL WT transfected cells, CBL Mt cells had increased MET expression; CBL shRNA knockdown cells 
also showed higher MET protein expression than control cells.
MET is one of the “driver” genes amplified or mutated in lung cancer15, 16, 20. MET enhances the tumor growth 
and is mutated and overexpressed in many solid tumors21. MET signaling pathway activation leads to cell pro-
liferation, survival, wound healing, motility, angiogenesis, tissue regeneration, scattering, and morphogenesis20. 
Studies have shown the MET mutation occurs on specific domains, e.g. juxtamembrane domain, which decreases 
the binding ability of CBL E3-ligase22. Previously, RTK overexpression and mutation were identified in many 
solid tumors. Recognizing oncogenic mutations of specific carcinomas allows clinicians to stop tumorigenic 
mechanisms by using novel targeted therapies. Unlike cytotoxic strategies, targeted therapies are often cytostatic 
whereas standard chemotherapy agents are cytotoxic. RTK signaling plays a role in frequent genetic aberrations 
in cell proliferation, tumorigenesis, metastasis, and angiogenesis; these important roles make RTK signaling an 
attractive target for anti-cancer therapies23, 24. The goal of this study was divided into three parts: first, to inves-
tigate whether MET is the target of CBL in lung cancer; second, to investigate whether CBL Mts affect the sensi-
tivity of cancer cells to specific cancer therapeutics; and third, to study the response of MET inhibitor SU11274 
when treated in A549 CBL isogenic cells. The results in A549 CBL isogenic cells showed the empty vector control 
and A549 CBL Mts S80N/H94Y, Q249E, V391I, and W802* cells that have very low expression of CBL and high 
expression of MET were more sensitive in MET inhibitor SU11274 treatment than CBL WT. Interestingly, there 
is no difference with erlotinib treatment (data not shown). According to the results shown in figure 1, CBL Mts 
decreased the ubiquitination of MET relative to CBL WT cells. This decreased ubiquitination brought about more 
MET protein expression in CBL Mts cells, suggesting that CBL Mts cells had more sensitivity in MET inhibitor 
SU11274 but not with erlotinib. In Table 2 we showed 10 CBL alteration NSCLC patients’ treatment outcome, 
Two out of ten patients had EGFR L858R/T790M mutations and had bad outcome after erlotinib treatment. Many 
studies have shown EGFR L858R/T790M cause drug resistance and poor response to gefitinib or erlotinib25–27. 
Later, we showed H1975 EGFR L858R/T790M mutation cells with CBL knockdown were sensitive with MET 
inhibitor SU11274 treatment but not with erlotinib. The investigation here showed a new strategy of treatment for 
EGFR L858R/T790M mutation patients who also have CBL alterations.
Figure 4. CBL knockdown increases colony formation and the cells were sensitive to MET inhibitor SU11274. 
(A) Soft agar colony formation assay showed colony formation of H358 sh-control and sh-CBL cells. sh-CBL 
cells showed more colonies and larger colony size than sh-control cells. (B and C) Show the colony number 
and size quantification respectively. (D) Soft agar colony formation assay showed colony formation of sh-
CBL cells alone and treated with MET inhibitor SU11274 had significant more colonies and inhibition by 
SU11274 respectively than sh-control cells. P-values were for comparison with sh-control cells. (*p < 0.05 and 
***p < 0.001).
www.nature.com/scientificreports/
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Since the loss of CBL (sh-CBL) and CBL Mts result in loss of function of CBL, we used shRNA knockdown 
CBL cells of A549 and H358 to investigate tumor growth and metastasis in mouse models. High rates of tumor 
metastasis were found in cell lines with knockdown CBL. The flank tumor of the sh-CBL group, however, did 
not grow as much as expected suggesting knockdown CBL changes the tumor phenotype and increases tumor’s 
ability to metastasize. The tumor cell no longer remains confined to the flank moves to distant sites. However, 
with MET inhibitor PHA665752 treatment, the sh-CBL group not only showed more tumor inhibition than 
sh-control group but also showed no metastasis in the lung after treatment. This metastatic model is more like a 
migration model from the subcutaneous site to the lung on cell migration in vitro. It is possible that there could 
be other mechanisms besides CBL/MET interactions that could lead to the in vivo tumor growth decrease with 
sh-CBL. What is important to note is that with sh-CBL, and MET small molecule inhibition, there is reduces the 
in vivo tumor growth beyond just sh-CBL. Further studies need to be performed to investigate the mechanism of 
Figure 5. The Heatmap of CBL mutations. (A) PamGene analysis was performed to detect the RTK 
phosphorylation difference between CBL WT and mutants. A549 CBL isogenic cells were treated with MET 
inhibitor SU11274. After treatment with SU11274, and in comparison with CBL WT, significantly changed 
peptides were shown as a heatmap. Red color represents the signal upregulation and the blue color represents 
the signal downregulation. (B) The protein expression of common targets in three CBL mutations was validated 
by immunoblotting. Protein expression was quantified and indicated with the fold change numbers shown 
below each immunoblot in comparison with WT. Each protein lysates of separated blot of were collected in the 
same time period for and the lysates were loaded in one gel per antibody staining. (C) Significantly different 
peptides were used to analyze affected signaling pathways by Ingenuity Pathway Analysis (IPA). PI3K/AKT, 
ephrin A, ERK/MAPK, and other signaling pathway were involved especially MET/HGF signaling pathway.
www.nature.com/scientificreports/
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metastasis and the relative paucity of growth at the original site of the tumor. And, that in the future, we should 
study the role of CBL as a potential predictive biomarker in anti-MET therapeutics.
In summary, this study showed that MET is regulated by CBL. The cell viability and motility results showed 
CBL Mts and sh-CBL cells are more sensitive than CBL WT cells to MET inhibitor SU11274. The increased 
sensitivity of CBL mutants to SU11274 suggests CBL mutants have higher expression of MET protein. Although 
MET expression in sh-CBL cells (Fig. 6) did not show dramatically different than sh-control cells, we suggest that 
those cells did not have 100% knockdown efficiency. Thus, MET expression was affected by endogenous CBL. As 
figure 1 shows, knockdown CBL does increase MET expression. This result can lead us to think about alternative 
therapeutic strategies in lung cancer patients who failed EGFR target therapy. The results of PamGene analysis 
indicate that MET is involved in CBL cell signaling transduction, especially in CBL-W802* cells, which are more 
sensitive to SU11274 compared to CBL WT treated with SU11274. Moreover, we noticed from kinome analysis 
results that Eph family (e.g. EPHA2) was also involved in CBL regulation. Some studies suggest that ligand stim-
ulation induces CBL phosphorylation and regulates Eph receptors degradation28, 29. Other studies have shown 
that EPHA2 internalized by ligand-mediated stimulation and then degraded by CBL30–33. In our other study, 
EPHA2 and its ligand ephrin A1 showed overexpression, but phosphorylated EPHA2 showed low-expression in 
NSCLC (Data not shown). This suggests CBL plays an important but unclear role in EPHA2 degradation. In con-
clusion, CBL gene status could be a potential target and indicator for MET inhibitors and future RTK regulation 
investigations, especially in those that will look into whether CBL should be evaluated before RTK inhibitors are 
considered.
Materials and Methods
Cell culture. Human non-small-cell lung carcinoma cell lines: A549, H358, H226, and H1975 (American 
Type Culture Collection, Manassas, VA) were maintained in RPMI1640 media supplemented with 10% fetal bovine 
serum (FBS), 100 units/ml of penicillin, and 100 µg/ml of streptomycin (Invitrogen, Carlsbad, CA). Cells were 
cultured at 37 °C in a humidified incubator containing 5% CO2.
CBL knockdown. 1 × 105 A549, H358, H226, and H1975 cells per well were seeded in 6-well plates and 
infected the following day with CBL lentiviral shRNA constructs (MISSION lentiviral transduction particles, 
Sigma-Aldrich, St. Louis, MO) per manufacturer’s instructions. To generate stable CBL knockdown cell lines 
(sh-CBL), steps were performed as described in previous work13.
CBL constructs and transfection. A549 CBL knockdown cells (A549 sh-CBL) were generated as described 
above. Plasmid DNA of CBL WT and four CBL Mts S80N/H94Y (SH), Q249E (Q), V391I (V), and W802* (W*) 
were previously generated13. These constructs were cloned into pLenti6.3/V5-TOPO vector and transfected into 
A549 sh-CBL cells using Fugene HD reagent (Roche, Nutley, NJ) according to the manufacturer’s instructions. 
Top Canonical Pathway p-value
PTEN Signaling 1.06E-04
Axonal Guidance Signaling 1.8E-04
Semaphorin Signaling in Neurons 9.7E-04
GDNF Family Ligand-receptor Interactions 1.29E-03
STAT3 Pathway 1.44E-03
Top Diseases and Bio Functions
Diseases and Disorders p-value
Cancer 2.06E-03
Respiratory Disease 2.06E-03
Molecular and Cellular functions p-value
Cell Cycle 1.03E-03
Cell Death and Survival 2.06E-03
Cellular Compromise 2.06E-03
Cellular Response to Therapeutics 2.06E-03
Cellular Development 1.23E-02
Top Networks
Associated Network Function Score*
Carbohydrate metabolism, Cellular Function and 
Maintenance, Cell-To-Cell Signaling and Interaction 2
Cell Morphology, Hematological System 
Development and Function, Inflammatory Response 2
Cellular Movement, Cell Death and Survival, Cancer 2
Cell Cycle, DNA Replication, Recombination, and 
Repair, Cancer 1
Table 1. Summary of PamGene IPA analysis. *The score of top networks is simply a measure of the number of 
genes significantly different from CBL WT or Mts in a network.
www.nature.com/scientificreports/
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Patient Tumor type CBL mutation
EGFR/
MET/KRAS 
mutation Chemo/Clinical Trial Outcome
1 Lung AD H37_H38insHH
EGFR 
E746_A750del, 
T790M
Erlotinib Was effective for a time but progressive disease
AP26113
1. Interval progression of disease with interval increase in the size of the 
left lung mass, hepatic metastases, also as metastases and left adrenal 
metastatic disease.
2. Interval development of right-sided pulmonary static disease.
2 Lung AD A848T
EGFR 
E746_A750del, 
amplification
Carboplatin Unknown. Tolerated Well
Paclitaxel Unknown. Tolerated Well
Erlotinib Good response but discontinued due to poor performance status
3 Lung AD T810S, amplification EGFR R429S
Carboplatin
1. No new suspicious pulmonary nodules or masses.
2. Stable upper mediastinal right paratracheal soft tissue mass at the site of 
prior resection.
Paclitaxel
1. No new suspicious pulmonary nodules or masses.
2. Stable upper mediastinal right paratracheal soft tissue mass at the site of 
prior resection.
4 NSCLC (NOS) S80G
Carboplatin Unknown
Gemcitabine Unknown
5 Lung AD A848T, E886K
EGFR R1068*, 
P518L; KRAS 
G10R, K169N
Carboplatin
1. No significant interval change in the large necrotic right anterior 
mediastinal mass with extension into the right hilum and right chest wall 
and sternal/pericardial/SVC invasion.
2. Mild interval improvement in number of pulmonary nodules, 
specifically in the right upper lobe.
3. Stable retroperitoneal lymphadenopathy.
4. Nonspecific sclerotic focus in vertebral body of T3.
Paclitaxel
1. No significant interval change in the large necrotic right anterior 
mediastinal mass with extension into the right hilum and right chest wall 
and sternal/pericardial/SVC invasion.
2. Mild interval improvement in number of pulmonary nodules, 
specifically in the right upper lobe.
3. Stable retroperitoneal lymphadenopathy. 4. Nonspecific sclerotic focus 
in vertebral body of T3.
6 Lung AD E366*
CALGB 30303, Phase II IRB 
13724 A trial of Docetaxel and 
Cisplatin
Unknown
Carboplatin Marked improvement of disease.
7 Lung AD R420Q KRAS G12C No Chemotherapy/Trial
8 NSCLC (NOS) K54E
Carboplatin
1. Good response.
2. Interval decrease in size of left upper lobe mass and left hilar/
subsegmental lymph node.
3. Left upper lobe mass is now mostly cavitary.
Paclitaxel
1. Good response.
2. Interval decrease in size of left upper lobe mass and left hilar/
subsegmental lymph node.
3. Left upper lobe mass is now mostly cavitary.
9 NSCLC (NOS) A757T
KRAS 
amplification, 
G12V
Cisplatin Clinically no evidence of disease
Docetaxel Clinically no evidence of disease
Carboplatin Response in some areas, but progression in right kidney (mixed response?)
Gemcitabine Response in some areas, but progression in right kidney (mixed response?)
10 Lung AD Amplification EGFR L858R
Carboplatin
1. No evidence of acute pulmonary embolus.
2. New geographic areas of groundglass opacities in the right lung.
3. Differential diagnosis includes drug toxicity, atypical infection, and 
hemorrhage.
4. Stable left lingular mass, sclerotic osseous foci, and metastatic hepatic 
lesions.
Paclitaxel
1. No evidence of acute pulmonary embolus.
2. New geographic areas of groundglass opacities in the right lung.
3. Differential diagnosis includes drug toxicity, atypical infection, and 
hemorrhage.
4. Stable left lingular mass, sclerotic osseous foci, and metastatic hepatic 
lesions.
Erlotinib Good response but discontinued due to poor performance status
Table 2. Foundation ONE reports of CBL alterations with EGFR, MET, or KRAS alterations and patient 
treatment outcome. AD: adenocarcinoma; NOS: not otherwise specified.
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After 48 hours, cells were harvested and analyzed for CBL expression. Cells were cultured in 5 mg/ml of blastici-
din (Invitrogen) for stable selection.
Cell viability assay. A549 CBL isogenic cells were transfected with CBL WT and Mts as described above. 
Forty-eight hours after transfection, cells were harvested and re-seeded at 5 × 104 cells/well in a 24-well culture 
plate. After 24 hours, cells were treated with 1 μM of MET inhibitor SU11274 for 48 hours. Cell viability was deter-
mined using Trypan Blue exclusion.
H1975 CBL knockdown cells were seeded 5 × 103/well in a 96-well culture plate. After 24 hours, cells were 
treated with MET inhibitor SU11274 and EGFR inhibitor, erlotinib, for 24, 48, and 72 hours. Cell viability was 
determined using Calcein-AM exclusion.
Ubiquitin ligase activity. This assay was performed as described in previous work34. Proteins were collected 
and blotted with anti-MET, anti-Ubiquitin, anti-HA, and anti-β-actin antibodies.
Immunoblotting. Cells were collected at 48 hours after transfection and performed a standard steps as previ-
ously described13. Antibodies were used at the following dilutions and obtained from Santa Cruz Biotechnologies 
(CBL, 1:500; MET, 1:1000; EGFR, 1:1000; Ubiquitin, 1:1000; HA, 1:1000; and β-actin, 1:2000), Cell Signaling 
Technology (Danvers, MA) (p-EPHA2 Y772, 1:1000; p-CD79A Y182, 1:1000), Abcam (Cambridge, MA) (p-p85 
Y607, 1:500), and OriGene Technologies (Rockville, MD) (p-PECAM Y713, 1:500). The immunoblotting results 
were quantified by ImageJ and Quantity Once software (Bio-Rad, Hercules, CA).
Wound healing assay. 5 × 104 H358 sh-CBL cells transfected as described in the transfection assay and/or 
treated with 1 μM of SU11274 were seeded in a wound healing assay insert (ibidi, Fitchburg, WI) for 24 hours. 
After removing the insert, the cells were then gently washed with 1X phosphate-buffered saline (PBS) to remove 
cellular debris and the media was replaced. Photographs of the wound region were taken every 3 hours until 
52 hours had passed. The images were analyzed using the TScratch software (Computational Science and 
Engineering Laboratory, ETH Zurich, Switzerland). The wound closure at each time point was quantified and 
normalized to 0 hr.
Soft agar colony formation assay. To investigate the potential of CBL cells tumorigenesis, 5 × 104 viable 
H358 and H226 sh-control and sh-CBL cells per well were seeded in soft agar in 6-well plates. The base layer was 
0.6% agar in 1X RPMI1640 medium and the top layer was 0.4% agar in 1X RPMI1640 medium. Cells were mixed 
in the top layer and grew for 4 weeks at 37 °C in a humidified atmosphere containing 5% CO2. Viable colonies 
were photographed and counted using ImageJ software (http://rsbweb.nih.gov/ij/). In the drug treatment study, 
H226 sh-control and sh-CBL cells were pretreated with 2 μM MET inhibitor SU11274 for 48 hours and 5 × 104 
viable cells per well were plated in soft agar in 6-well plates, following the same experimental procedure described 
above.
PamGene technology and analysis. PamGene technology uses the PamChip® Tyrosine Kinase Array of 
the phosphorylation of peptides spotted onto a 3-dimensional porous well of a 4-array chip produced and com-
mercialized by PamGene (s-Hertogenbosch, The Netherlands). There are 144 peptides on each array. PamGene 
measures the activity of kinases in whole cell lysates. Evaluating the effects of CBL on the phosphor-kinome was 
performed as previously described by the PamGene platform35, 36.
The kinase activity of A549 CBL isogenic cells with and without MET inhibitor SU11274 was monitored. In 
brief, cells were treated with SU11274, harvested and lysed in Mammalian Extraction Buffer (M-PER, Pierce) 
containing phosphatase and protease inhibitors (HALT, Pierce). Five μl of the lysis solution was pipetted into a 
reaction mixture composed of 1X ABL buffer (New England Biolabs), 0.1% Bovine Serum Albumin, 100 μM ATP, 
Figure 6. MET and EGFR inhibition in EGFR mutation cell line H1975. (A) CBL, MET, p-MET, EGFR, and 
p-EGFR protein expression in H1975 CBL knockdown cells. Protein expression was quantified and indicated 
with the fold change numbers shown below each immunoblot in comparison with parental H1975 cells. Each 
protein lysates of separated blot of were collected in the same time period for and the lysates were loaded in one 
gel per antibody staining. (p: parental, c: sh-control). (B) MET inhibitor SU11274, (C) EGFR inhibitor erlotinib, 
and (D) SU11274 and erlotinib combination were used to treat H1975, H1975 sh-control, and H1975 sh-CBL 
cells with variant dosages for 24 hr. *p < 0.05, **p < 0.01. RFU: relative fluorescence units.
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Figure 7. Tumor growth of CBL knockdown cells in mouse xenograft model. (A) Tumor was assessed three 
times a week. sh-control (con) of A549 and H358 cells showed more rapid growth of tumor than sh-CBL (CBL) 
cells. (B) Tumor weight of sh-CBL groups in A549 and H358 cells showed a significant difference compared 
with sh-control (* p < 0.05). (C) Photograph of tumors from 4 mice of sh-control and sh-CBL groups in A549 
and H358 cells. (D) H&E staining of primary tumors from sh-control and sh-CBL groups in A549 and H358 
cells at 10x, 20x, and 60x magnifications. (E) Metastasis study of CBL knockdown cells in vivo. H&E staining of 
lung tumors showed more tumor metastasis results by pathologist’s reading from the subcutaneous injection 
site to the lung in both A549 and H358 sh-CBL cells than in sh-control cells. Metastatic tumors shown by black 
arrows.
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20 μg/ml phosphor-tyrosine antibody in a total volume of 40 μl. PamChips arrays were blocked with 0.2% BSA 
prior to loading the samples. After loading the reaction mixtures onto the Pamchip arrays real time data for the 
kinase activity were obtained by measuring fluorescence of the bound anti-phospho-tyrosine antibody after each 
of the 5 cycles. Image quantification and data processing were conducted with dedicated Pamgene software Evolve 
and BioNavigator (PamGene). The peptides that were significantly differentially affected peptides and signaling 
pathways were analyzed using Ingenuity Pathway Analysis (IPA) (Redwood City, CA).
Tumor growth and metastasis analysis in vivo. A459 and H358 sh-control and sh-CBL cells were cul-
tured in RPMI1640 medium with 10% FBS and 1% penicillin/streptomycin at 37 °C in a humidified incubator 
containing 5% CO2. Once the cells reached a 60% of density, cells were trypsinized and harvested in HBSS. 
Eight-week-old SCID/Beige mice were used for this study. Viable cells (5 × 106) were suspended in 0.1 ml sterile 
PBS and were injected into the right suprascapular region of each mouse. Tumor burden was measured using 
bisecting diameters with calipers. Tumor volume of each group was plotted against time. Tumor volume was cal-
culated using the formula 0.4ab2 (a = large diameter and b = small diameter). Tumor and perfused lung samples 
were fixed in 4% formalin, embedded in paraffin, and stained with hematoxylin and eosin (H & E). Once the 
animals were sacrificed, the tumors weights were determined.
For drug inhibition investigation, female BALB/c nude mice, age 5–6 weeks, were used after obtaining appro-
priate Institutional Review Board (IRB) approval and raised in a pathogen-free environment. H358 sh-control 
and sh-CBL cells (5 × 106) in a volume of 200 μl were implanted subcutaneously into the mice. H358 sh-control 
and sh-CBL xenograft were treated with MET inhibitor PHA665752 (150 μg/50 μl of 2% DMSO) by intraperito-
neal (i.p.) continually for 8 days after tumor nodule size reach to 50 mm3. Tumors were measured with calipers 
and collected.
All experiments and animal care were performed in accordance with Institutional Animal Care and Use 
Committees (IACUC) animal care guidelines and the University of Chicago Automating University-wide 
Research Administration (AURA) Institutional Biosafety Committee (IBC) approval.
Clinical data interpretation. All the clinical data and the associated molecular data presented in this pro-
ject were queried from the University of Chicago’s Thoracic Oncology Research Program (TORP) database. The 
TORP database is comprised of four component databases: the Microsoft Access database, the Velos database, 
the REDCap database, and the Microsoft Excel database. For this project, we mainly utilized the Access database 
for acquiring the necessary data. The Access database serves as the central repository for clinical, demographical, 
research, and molecular data.
In the process of obtaining the clinical and molecular data, patients were first consented onto the 9571 and 
13473 A, which are both IRB approved protocols. These two protocols authorize the use of retrospectively and/or 
prospectively collected of biospecimens, as well as associated clinical, demographical, and molecular data. After 
patients were consented, patient data were extracted from electronic medical health records and transferred into 
the Access database by the TORP’s data manager. The data manager then performed querying functions in the 
Access database to acquire the necessary data for the project and performed in accordance with relevant guide-
lines and regulations.
Figure 8. Tumor inhibition by MET inhibitor PHA665752 in vivo. (A) Tumor from sh-CBL, sh-CBL treated 
with PHA665752, and sh-control treated with PHA665752 groups showed growth inhibition compared with 
the sh-control group. *p < 0.05 (B) Photographs of tumors from 5 mice of each group: sh-control, sh-control 
treated with PHA665752, sh-CBL, and sh-CBL treated with PHA665752.
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Statistical analysis. Experiments involving repeated measurements over time were analyzed using repeated 
measures analysis of variance (ANOVA) with the Greenhouse-Geisser adjustment. Group comparisons were 
done by ANOVA with the Sidak adjustment. Analyses were conducted using STATA (v10.1) software (Stata 
Corporation, College Station, TX).
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